Erudio Healtherudio.com
Clinical trial · no report yet · Phase not applicable
PR.19
Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
- NCT02960087 ↗
- Active, not recruiting
- Canadian Cancer Trials Group
- Standard
We haven't built an HCP commentary report on PR.19 (Prostate Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PR.19 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 12 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
- Phase
- Phase not applicable
- Status
- Active, not recruiting
- Conditions
- Prostate Carcinoma
- Interventions
- Low dose rate brachytherapy; High dose rate brachytherapy
- Arms
- Arm 1 LDR · Active comparator
- Arm 3 HDR · Active comparator
- Enrollment
- 334
- Primary outcomes
- Efficacy of HDR and LDR brachytherapy on prostate cancer control as defined by 48 month PSA values
- Sponsor
- Canadian Cancer Trials Group
- Start
- Mar 6, 2017
- Primary completion
- Apr 30, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT02960087 · updated Apr 22, 2026